Liu F T, Hsu D K, Zuberi R I, Hill P N, Shenhav A, Kuwabara I, Chen S S
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037-1093, USA.
Biochemistry. 1996 May 14;35(19):6073-9. doi: 10.1021/bi952716q.
Galectin-3 is a member of a newly defined family of animal lectins, which is composed of three domains: a small amino-terminal domain, a domain containing repeating elements, and a carboxyl-terminal domain containing the carbohydrate-recognition site. Various functions have been described or proposed for this lectin, and it appears that galectin-3 has diverse roles. Murine monoclonal antibodies (MAbs) have been generated from mice hyperimmunized with recombinant human galectin-3 or galectin-3C (the carboxyl-terminal domain), and seven MAbs have been characterized in detail. All MAbs generated against the intact galectin-3 recognize the amino-terminal region of the molecule, as demonstrated by ELISA and immunoblotting using recombinant galectin-3C and galectin-3NR, which contains the amino-terminal domain and all the repeating elements. Their epitopes were all found to be within the first 45 amino acids of galectin-3, as determined by using galectin-3 mutants with a truncated amino-terminal region. However, these MAbs were found to profoundly modulate the lectin activities of galectin-3. The MAb B2C10 inhibited (i) the binding of 125I-labeled galectin-3 to IgE coated on microtiter plates; (ii) the galectin-3's hemagglutination activity; and (iii) galectin-3-induced superoxide production by human neutrophils. Other MAbs, especially A3A12, caused marked potentiation of these activities. The results support our model that the lectin function of galectin-3 is influenced by protein homodimerization resulting from self-association of the amino-terminal region of the molecule. The potentiating activities of some MAbs are probably due to facilitation of dimerization galectin-3, and the inhibitory activity of MAb B2C10 is probably the result of its disruption of the self-association process.
半乳糖凝集素-3是新定义的动物凝集素家族的成员,由三个结构域组成:一个小的氨基末端结构域、一个包含重复元件的结构域和一个含有碳水化合物识别位点的羧基末端结构域。关于这种凝集素已经描述或提出了各种功能,并且半乳糖凝集素-3似乎具有多种作用。用重组人半乳糖凝集素-3或半乳糖凝集素-3C(羧基末端结构域)对小鼠进行超免疫后产生了鼠单克隆抗体(MAb),并对七种MAb进行了详细表征。如使用重组半乳糖凝集素-3C和半乳糖凝集素-3NR(其包含氨基末端结构域和所有重复元件)通过ELISA和免疫印迹所证明的,所有针对完整半乳糖凝集素-3产生的MAb都识别该分子的氨基末端区域。通过使用具有截短氨基末端区域的半乳糖凝集素-3突变体确定,它们的表位都位于半乳糖凝集素-3的前45个氨基酸内。然而,发现这些MAb能深刻调节半乳糖凝集素-3的凝集素活性。单克隆抗体B2C10抑制:(i)125I标记的半乳糖凝集素-3与包被在微量滴定板上的IgE的结合;(ii)半乳糖凝集素-3的血凝活性;以及(iii)半乳糖凝集素-3诱导的人中性粒细胞超氧化物生成。其他单克隆抗体,尤其是A3A12,导致这些活性显著增强。这些结果支持我们的模型,即半乳糖凝集素-3的凝集素功能受分子氨基末端区域自缔合导致的蛋白质同源二聚化影响。一些单克隆抗体的增强活性可能是由于促进了半乳糖凝集素-3的二聚化,而单克隆抗体B2C10的抑制活性可能是其破坏自缔合过程的结果。